GB Sciences, Inc., OTCQB: GBLX, a leading plant-inspired biopharmaceutical R D development company, recently published a study showing the potential of selected cannabinoids and terpenes to reduce inflammation. The company is developing anti-inflammatory, cannabinoid-based therapeutics to combat viral infections in the future.
According to a press release, 6.3 million died from the hyperinflammatory side effects associated with the viral infection during the pandemic, which inspired Gb Sciences to create anti-inflammatory drugs designed to treat future viral outbreaks that elicit these dangerous hyperinflammatory responses.
Andrea Small-Howard, president and chief science officer of Gb Sciences, said their cannabis-inspired therapies were designed to reset the immune system after hyperinflammation has been triggered, providing relief by targeting our immune response to a virus, without being tied to a specific variant or the virus itself. Gb Sciences' CRS therapy stands out due to early intervention and preventive opportunities for patients who have been exposed to a virus that causes hyperinflammation.
This therapy may be useful for patients with CRS as a side effect of certain new cancer therapeutics, such as Bispecific T-cell engaging BiTE single-chain antibody constructs and chimeric antigen receptor CAR T-cells, per the press release.
Early in May, the company announced that FHI Clinical would write and consult on the draft clinical trial protocol for the first human trial of these proprietary cannabinoid-containing formulations.
A proof-of- concept study by Michigan State University examined the potential for Gb Sciences cannabis-derived mixtures to suppress immunological responses that contribute to virus symptoms, according to its novel development program.
The global anti-inflammatory therapeutics market size is estimated to be $99.6 billion in 2021, and is expected to reach $127.5 billion by 2030, with a CAGR of 4.5% from 2022 to 2030.
Get your daily dose of cannabis news on Benzinga Cannabis.